Literature DB >> 15655052

Reasons for non-treatment of hepatitis C in veterans in care.

A A Butt1, M Wagener, A O Shakil, J Ahmad.   

Abstract

We prospectively studied 354 patients with hepatitis C virus (HCV) infection who were referred to a hepatology specialty clinic to find the reasons for non-treatment of HCV. The median age was 48 years (range 27-77 years), 98.5% were male and 71% were white. Seventy per cent of the patients were not treated. The most common reasons for non-treatment were non-adherence to follow-up visit (24%), normal liver enzymes (14%), concurrent medical problems (11%), alcohol and drug use (9%), psychiatric problems (7%), advanced liver disease (7%), referral for transplant evaluation (6.4%) and patient refusal, transfer of care to another facility and non-detectable HCV RNA levels (5% each). The reason was not recorded for 5% of the patients and was treatment deferred in 2.4% while waiting for pegylated interferon approval. Non-treatment was more likely in patients with less than 12 years of education and a history of incarceration. Patients who were lost to follow-up and refused treatment were more likely to have current alcohol and drug use and a history of incarceration.

Entities:  

Mesh:

Year:  2005        PMID: 15655052     DOI: 10.1111/j.1365-2893.2005.00547.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  30 in total

1.  Developing a modified directly observed therapy intervention for hepatitis C treatment in a methadone maintenance program: implications for program replication.

Authors:  R Douglas Bruce; Julie Eiserman; Angela Acosta; Ceilia Gote; Joseph K Lim; Frederick L Altice
Journal:  Am J Drug Alcohol Abuse       Date:  2012-01-13       Impact factor: 3.829

2.  Rate, delay and predictors of hepatitis C treatment in British Columbia.

Authors:  Alan Hoi Lun Yau; Terry Lee; Alnoor Ramji; Hin Hin Ko
Journal:  Can J Gastroenterol Hepatol       Date:  2015-04-15

3.  Identification of novel human kinases that suppress hepatitis C virus infection.

Authors:  A Lee; S Liu; T Wang
Journal:  J Viral Hepat       Date:  2013-11-10       Impact factor: 3.728

4.  Hepatitis C treatment completion rates in routine clinical care.

Authors:  Adeel A Butt; Kathleen A McGinnis; Melissa Skanderson; Amy C Justice
Journal:  Liver Int       Date:  2009-11-04       Impact factor: 5.828

Review 5.  Barriers to hepatitis C treatment.

Authors:  Christopher E McGowan; Michael W Fried
Journal:  Liver Int       Date:  2012-02       Impact factor: 5.828

6.  Access to care for vulnerable veterans with hepatitis C: a hybrid conceptual framework and a case study to guide translation.

Authors:  Catherine Rongey; Steven Asch; Sara J Knight
Journal:  Transl Behav Med       Date:  2011-12       Impact factor: 3.046

7.  Effect of race and HIV co-infection upon treatment prescription for hepatitis C virus.

Authors:  Adeel A Butt; Joel Tsevat; Anthony C Leonard; Obaid S Shaikh; Deborah McMahon; Uzma A Khan; Zachariah Dorey-Stein; Vincent Lo Re
Journal:  Int J Infect Dis       Date:  2008-11-06       Impact factor: 3.623

8.  Awareness of hepatitis C infection among women with and at risk for HIV.

Authors:  Mardge H Cohen; Dennis Grey; Judith A Cook; Kathryn Anastos; Eric Seaberg; Michael Augenbraun; Pam Burian; Marion Peters; Mary Young; Audrey French
Journal:  J Gen Intern Med       Date:  2007-10-09       Impact factor: 5.128

9.  Patients' preferences for treatment of hepatitis C.

Authors:  Liana Fraenkel; Diane Chodkowski; Joseph Lim; Guadalupe Garcia-Tsao
Journal:  Med Decis Making       Date:  2009-07-27       Impact factor: 2.583

10.  High deferral rates and poorer treatment outcomes for HCV patients with psychiatric and substance use comorbidities.

Authors:  Donna M Evon; Amit Verma; Karen A Dougherty; Betty Batey; Mark Russo; Steven Zacks; Roshan Shrestha; Michael W Fried
Journal:  Dig Dis Sci       Date:  2007-03-30       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.